The Comparative Study With Lixisenatide /Glargine Combination Therapy Versus Twice-Daily Premixed Insulin Therapy/DPP-4 Inhibitor on Glycemic Variability, and Feeding Behavior in Obese Patients With Type 2 Diabetes Mellitus

Health and Primary Care

doi 10.15761/hpc.1000149

Full Text

Abstract

Available in

Date

Authors

Publisher

Open Access Text Pvt, Ltd.

Related search

The Risk of Severe Hypoglycemia in Patients With Type 2 Diabetes Mellitus Starting Insulin Therapy With Premixed Insulin Analogues Taken Twice Daily: An Observational Study in Turkish Patients

Turkish Journal of Endocrinology and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2013English

Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) as Add-On Therapy in Chinese Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Observational Study of the Use of Insulin Glargine as Basal Therapy in Patients With Type 2 Diabetes Mellitus in Morocco

Journal of Endocrinology and Metabolism
EndocrinologyMetabolismDiabetes
2015English

DPP-4/SGLT2 Inhibitor Combined Therapy for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Cost-Effectiveness of Insulin Degludec Compared With Insulin Glargine for Patients With Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Glycemic Variability and Vascular Complications in Patients With Type 2 Diabetes Mellitus

Folia Medica
Medicine
2017English

Combination Therapy With DPP-4 Inhibitors and Pioglitazone in Type 2 Diabetes: Theoretical Consideration and Therapeutic Potential

Vascular Health and Risk Management
2008English

Efficacy and Safety of 1:1 Fixed Ratio Combination of Insulin Glargine/Lixisenatide (iGlarLixi) Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial

2020English

Efficacy and Safety of 1:1 Fixed Ratio Combination of Insulin Glargine/Lixisenatide (iGlarLixi) Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy